亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都云希化工生物有限公司  

美容肽、藥物肽、定制肽、醫藥中間體、化妝品原料

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:袁嬌
  • 電話:86-028-62328193
  • 郵件:zoe@youngshechem.com
  • 傳真:86-028-62328193
  • 微信:youngshe007
  • QQ:3211919385
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 棕櫚酰三肽-56
棕櫚酰三肽-56
單價 面議對比
詢價 暫無
發貨 四川成都市付款后3天內
庫存 5000克起訂1克
品牌 成都云希化工
過期 長期有效
更新 2020-03-31 17:05
 
詳細信息

云希產品簡介----棕櫚酰三肽-56

 

N-Prolyl Palmitoyl Tripeptide-56 Acetate促進膠原蛋白纖維產生和成熟,重建功能性的網狀結構;通過確保細胞骨架的完整性來重啟細胞核與細胞外基質的連接;作用于多種對細胞和真皮形態學有關鍵作用的因子。

 

云希產品參數----棕櫚酰三肽-56

 

中文名稱:棕櫚酰三肽-56

英文名稱:N-Prolyl Palmitoyl Tripeptide-56 Acetate, Matrixyl Morphomics

CAS號:1228371-11-6

純度:≥98%

分子量 :582.28g/mol

分子式 :C24H38N8O9

外觀:白色粉末或液體

儲存條件:2 ℃~8 ℃

包裝規格(粉末):1g, 10g, 100g

包裝規格(液體):20ml/瓶,1KG/瓶

應用:化妝品原料

 

云希功效與應用----棕櫚酰三肽-56

抗皺抗衰,眉間紋、法令紋、木偶紋

去除眼部皺紋和眼角魚尾紋

抗皺抗衰老產品、護膚品、修復產品。

 云希作用機理----棕櫚酰三肽-56
N-Prolyl Palmitoyl Tripeptide-56 Acetate應用于皮膚其效果是多方面的:顯著抗皺

 

 

 

INCI Name: N-Prolyl Palmitoyl Tripeptide-56 Acetate (Matrixyl Morphomics)

Cas No: 1228371-11-6

Formula: C24H38N8O9

Molecular: 582.28

Sequence:

Purity: >95%

Solubility: slightly soluble in water

Source: synthetic

MSDS and COA: available for your reference

Delivery: promptly from stock

 

N-Prolyl Palmitoyl Tripeptide-56 Acetate supports the reduction of vertical lines(frown lines, marionette lines, nasogenian fold) but also crow's feet after 6 weeks, for a happier expression.

©2025 成都云希化工生物有限公司 版權所有   技術支持:化工網   訪問量:6108  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |